Korlym Diabetes Efficacy
Corcept presents new data at ADA on Korlym's improved outcomes for difficult-to-control Type 2 Diabetes.
Corcept Therapeutics revealed new data at the American Diabetes Association's 86th Scientific Sessions on June 6, 2026, showing that patients taking Korlym® alongside a GLP-1 drug — like Ozempic or Mounjaro — had better outcomes than those on Korlym alone. Business Wire reported that the data came from two large trials, CATALYST and MOMENTUM, both targeting patients whose diabetes and blood pressure refuse to respond to standard treatment.
The headline number: 24% of difficult-to-control Type 2 diabetes patients have unrecognized hypercortisolism — meaning too much cortisol quietly driving their disease. That is roughly 1 in 4 patients who, according to Corcept, may be failing treatment for a hidden reason that a simple $10 blood test could catch.
GLP-1 Plus Korlym Delivers Stronger Results Than Either Alone
The CATALYST trial screened 1,057 patients with difficult-to-control Type 2 diabetes — defined as HbA1c between 7.5% and 11.5% despite multiple medications. Among those treated with Korlym, HbA1c dropped by 1.3 percentage points. But patients already on a GLP-1 drug saw a 1.7-point drop, according to MarketScreener.
The weight loss numbers told the same story. The overall Korlym group lost 5.1 kg and shed 5.1 cm from their waist. The GLP-1 subset lost 6.1 kg and 6.5 cm. Corcept's Chief Development Officer Bill Guyer said it is now clear that hypercortisolism is "more common than previously assumed in patients whose diabetes don't respond to standard-of-care," according to Business Wire.
Hypercortisolism Hidden in Millions of Resistant Patients
Hypercortisolism — sometimes called Cushing's syndrome — was once seen as a rare disease. Doctors looked for extreme signs like a rounded face or a fat hump on the upper back. The CATALYST and MOMENTUM trials tested a different idea: that a milder, silent form of the condition is quietly sabotaging treatment in millions of patients, according to Weekly Voice.
MOMENTUM screened 1,086 patients with resistant high blood pressure and found 27.3% had hypercortisolism. In the highest-risk group — patients with both high HbA1c and three or more blood pressure drugs — the rate jumped to 32.6% in MOMENTUM and 36.6% in CATALYST. Dr. Deepak Bhatt of Mount Sinai, the MOMENTUM lead investigator, said the trial shows hypercortisolism "contributes to resistant hypertension in over a quarter of patients."
Medical Community Split on Whether 1-in-4 Rate Is Too Broad
Not everyone welcomes the findings without question. Some experts writing in the journal Diabetes Care warn that the term "hypercortisolism" may be used too loosely. They argue that a positive result on a dexamethasone suppression test — the simple $10 screen — can catch cases that are stress-related rather than driven by a real tumor or gland problem, according to Financial Content.
Supporters push back hard. Dr. John Buse of the University of North Carolina, the CATALYST lead investigator, said it is "critical for clinicians to consider and address all factors" contributing to poor glucose control. His view: cortisol is one factor doctors have long ignored. The debate matters because Korlym is a potent drug — mifepristone — with real side effects and a high cost.
Wall Street Sees a Market Expanding From Thousands to Millions
Investors responded positively to the ADA data. H.C. Wainwright kept a Buy rating with a $95 price target, calling the findings a "paradigm shift" in diabetes screening. Piper Sandler held a Buy at $88, flagging the GLP-1 synergy as a "key commercial catalyst." UBS set the high end at a $135 target, pointing to what it called a "dual-engine" growth strategy, according to Barchart.
The financial stakes are large. Korlym was originally approved in 2012 for a few thousand patients with Cushing's syndrome. If 24% of the roughly 10 million Americans with difficult-to-control diabetes have unrecognized hypercortisolism, the addressable market grows dramatically. Corcept raised its 2026 revenue guidance to between $950 million and $1.05 billion, up from $157.2 million in quarterly revenue just a year ago.
Sentiment
NeutralPublishers
5
Articles
5
Reach
5
